Zobrazeno 1 - 10
of 357
pro vyhledávání: '"HIROKI HARA"'
Autor:
Takashi Oshima, Sachiko Yamamoto, Hisato Kawakami, Tomoki Makino, Akihito Kawazoe, Toshiki Masuishi, Takahiro Tsushima, Motohiro Hirao, Masahiro Tsuda, Kaori Hino, Noboru Yamamoto, Hiroki Hara, Shota Kaname, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Akira Ooki
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-7 (2024)
Abstract Background Esophageal cancer is one of the most common types of cancer in Japan. Herein, we report the efficacy and safety of E7389-LF plus the immune checkpoint inhibitor, nivolumab, from the esophageal cancer cohort of the phase 2 part of
Externí odkaz:
https://doaj.org/article/7dbdc5c5725f466f9c680a126d352047
Autor:
Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Shigemichi Iwae, Naoki Nishio, Yusuke Onozawa, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Ryo Kitabayashi, Keita Sasaki, Akihiro Homma, the Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG‐HNCSG)
Publikováno v:
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
Abstract Background In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m2) was non‐inferior to 3‐weekly cisplatin (100 mg/m2) for postoperative high‐risk head and neck cancer. We investigated how acute kidney injury (AKI), a
Externí odkaz:
https://doaj.org/article/c43d9154c4ec47eeb5d4f8c6e13452c3
Autor:
Kotaro Sugawara, Daiji Oka, Hiroki Hara, Takako Yoshii, Hiroki Ushijima, Shigehiro Kudo, Takashi Fukuda
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Little is known about predictive factors for survival outcomes of esophageal carcinoma (EC) patients who developed recurrence after undergoing multimodal therapies. We aimed to investigate long-term outcomes and identify prognosti
Externí odkaz:
https://doaj.org/article/211f3aff78354d2db8b29653d9af0249
Autor:
Naoya Sakamoto, Saori Mishima, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Takayuki Yoshino, Takeshi Kuwata, Kohei Shitara, Yoshiaki Nakamura, Daisuke Kotani, Masashi Wakabayashi, Shohei Koyama, Hiroyoshi Nishikawa, Yosuke Tanaka, Shogo Takei, Itaru Endo, Motohiro Kojima, Toshihide Ueno, Hiroyuki Mano, Shota Fukuoka, Yi-Tzu Lin, Hiroki Hara, Shinya Kojima
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background Immune checkpoint inhibitor (ICI) combinations represent an emerging treatment strategies in cancer. However, their efficacy in microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal cancer (CRC) is variable. Here, a m
Externí odkaz:
https://doaj.org/article/2be9529f9843474fb27cb25f1bcfd88c
Autor:
Shin Kobayashi, Hideaki Bando, Akinobu Taketomi, Takeshi Takamoto, Eiji Shinozaki, Manabu Shiozawa, Hiroki Hara, Kentaro Yamazaki, Koji Komori, Nobuhisa Matsuhashi, Takeshi Kato, Yoshinori Kagawa, Mitsuru Yokota, Eiji Oki, Keigo Komine, Shinichiro Takahashi, Masashi Wakabayashi, Takayuki Yoshino
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background The optimal treatment strategy for resectable BRAF V600E mutant colorectal oligometastases (CRM) has not been established due to the rarity and rapid progression of the disease. Since the unresectable recurrence rate is high, deve
Externí odkaz:
https://doaj.org/article/5e784c72c7d94e84b831f8b45905a952
Autor:
Naoki Takahashi, Hiroki Hara, Kengo Nagashima, Kenro Hirata, Toshiki Masuishi, Toshihiko Matsumoto, Hisato Kawakami, Kentaro Yamazaki, Shuichi Hironaka, Narikazu Boku, Kei Muro
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Trifluridine/tipiracil (FTD/TPI) prolongs survival in the third- or later-line treatment for advanced gastric cancer (GC), esophagogastric junction (EGJ) adenocarcinoma, and colorectal cancer. While single-arm phase II trials show
Externí odkaz:
https://doaj.org/article/7e4e091163904bb1a0330ed3bafd6354
Autor:
Yutaka Fujiwara, Yasutoshi Kuboki, Masayuki Furukawa, Nobumasa Mizuno, Hiroki Hara, Tatsuya Ioka, Makoto Ueno, Yasuo Takahashi, Shunji Takahashi, Shinji Takeuchi, Christine Lihou, Tao Ji, Chenwei Tian, Toshio Shimizu
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10597-10611 (2023)
Abstract Background FIGHT‐102 was a phase 1, dose‐escalation, dose‐expansion study of pemigatinib in Japanese patients with advanced solid tumors. Here, we report safety, tolerability, and preliminary efficacy of pemigatinib from FIGHT‐102. M
Externí odkaz:
https://doaj.org/article/9baedb4c4d12487081450e5da764609a
Autor:
Hiroki Hara, Jiro Yoshinari, Kenji Sasaki, Takashi Kikukawa, Hiroshi Take, Tetsuya Mino, Atsushi Shimura, Yasuhiro Takagi, Hideaki Fukuzawa
Publikováno v:
AIP Advances, Vol 14, Iss 1, Pp 015045-015045-5 (2024)
In this study, lithium niobate (LN) optical modulator devices were fabricated using cost-effective sputtered LN thin films. We successfully achieved a significantly small product of half-wave voltage and interaction electrode length (VπL) of 1.2, 1.
Externí odkaz:
https://doaj.org/article/97fd0826af874c388aa8d436baf54679
Autor:
Yuichiro Doki, Makoto Ueno, Chih‐Hung Hsu, Do‐Youn Oh, Keunchil Park, Noboru Yamamoto, Tatsuya Ioka, Hiroki Hara, Manabu Hayama, Masahiro Nii, Keiko Komuro, Mariko Sugimoto, Makoto Tahara
Publikováno v:
Cancer Medicine, Vol 11, Iss 13, Pp 2550-2560 (2022)
Abstract Background Agents targeting the programmed cell death‐1 pathway have demonstrated encouraging activity across multiple solid tumor types. The dose expansion phase of this phase I study evaluated the safety, tolerability, and antitumor acti
Externí odkaz:
https://doaj.org/article/72cee212174440e8a67e123a8cdd7829
Autor:
Akira Ooki, Satoshi Morita, Akihito Tsuji, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Suto, Yojiro Hashiguchi, Taichi Yabuno, Masahiko Ando, Junichi Sakamoto, Kensei Yamaguchi
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Purpose Although early tumor shrinkage (ETS) is a predictor of improved overall survival (OS), the association between ETS and health-related quality of life (HRQOL) remains unclear for patients with metastatic colorectal cancer (mCRC) treat
Externí odkaz:
https://doaj.org/article/8e277a2749b9411aa5325e80e6e2203a